INTRODUCTION
The addition of an adenine tail (poly(A)) to messenger RNA (mRNA) 3 0 ends is a cotranscriptional nuclear process that is important for nuclear export, translation, and mRNA stability (Lemay et al., 2010) . mRNA polyadenylation is a two-step process consisting of an endonucleolytic cleavage and addition of an untemplated poly(A) tail. Adjacent cis-acting motifs direct cleavage position and efficiency. Mainly, an upstream hexamer polyadenylation signal (PAS) and a downstream UG-rich sequence recruit the cleavage and polyadenylation specificity factor (CPSF) and the cleavage-stimulating factor (CSTF), respectively, both required for the polyadenylation process (Bentley, 2005; Zhang et al., 2010) . The canonical PAS is AAUAAA, which appears in about half of the cleavage sites (CSs). More than ten variants of the canonical PAS have been reported, and the most prominent among them is AUUAAA (Beaudoing et al., 2000; Tian et al., 2005) . mRNA poly(A) tails are added by a highly evolutionary conserved poly(A) polymerase (PAP) and recruit poly(A)-binding proteins (PABPs), which come in two flavors, the cytosolic PABPC and the nuclear PABPN1. The nuclear PABPN1 is structurally and functionally different from PABPC and is thought to function during poly(A) tail addition to mRNAs. In vitro, efficient polyadenylation requires CPSF, PAP, and PABPN1 (Kü hn et al., 2009; Wahle, 1995) . Whereas CPSF binds to PAS to cleave mRNAs and modestly stimulates polyadenylation, PABPN1 addition to CPSF/PAP strongly stimulates polyadenylation.
Most mammalian mRNAs contain a 3 0 untranslated region (3 0 UTR) that plays a key role in regulating mRNA stability, localization, and translation efficiency (Andreassi and Riccio, 2009; Fabian et al., 2010) . These functions are mediated mostly through binding of microRNAs (miRNAs) and RNA-binding proteins (RBPs) to regulatory elements embedded in the target 3 0 UTRs. miRNAs are small, noncoding RNAs that guide miRNP complexes to 3 0 UTRs by sequence-specific interaction with 3 0
UTRs based on a 6-8 seed sequence at their 5 0 ends (Fabian et al., 2010) . miRNAs are predicted to target the majority of human protein-coding genes, enabling them to play numerous regulatory roles in many physiological and developmental processes (Kedde and Agami, 2008) . RBPs, like miRNAs, are key components in gene expression regulation. They can either bind specific sequence elements on mRNAs (e.g., the human Pumilio RBP family) or looser consensus sequences, such as U-and A/U-rich motifs, to control expression in a negative or positive manner (Filipowicz et al., 2008) . Moreover, RBPs can bind 3 0 UTRs and interfere or stimulate miRNA function (Kedde et al., 2007 (Kedde et al., , 2010 . Thus, it appears that 3 0 UTRs can be viewed as regulatory platforms that determine mRNA stability, subcellular localization, and rate of protein synthesis (van Kouwenhove et al., 2011) .
The number of human and mouse genes reported to use alternative cleavage and polyadenylation (APA) to generate multiple mRNA isoforms with different 3 0 UTR lengths is continuously increasing and already passes the 50% estimate (Fu et al., 2011; Jan et al., 2011; Lutz, 2008; Ozsolak et al., 2010; Shepard et al., 2011; Tian et al., 2005) . Therefore, APA is emerging as an important layer in gene regulation as it modulates the inclusion of target sites for miRNAs and RBPs in 3 0 UTRs. Already more than a decade ago, it was shown that changes in the concentration of CstF could affect APA of IgM heavy-chain transcripts during B cell development (Takagaki and Manley, 1998; Takagaki et al., 1996) . Recently, it was observed that whereas primary human cells mostly use distal PASs, usage of proximal sites, which results in 3 0 UTR shortening, is enhanced during cell activation (Sandberg et al., 2008) , early in development (Ji et al., 2009) , and in cancer (Mayr and Bartel, 2009 ; for a recent review, see Di Giammartino et al., 2011) . However, factors that regulate APA during cancer progression and differentiation are still largely unknown.
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal-dominant form of late-onset (patients aged >40 years), slowly progressive myopathy, characterized by bilateral eyelid ptosis (drooping), dysphagia (swallowing difficulties), and proximal limb weakness (Rü egg et al., 2005) . Beyond the age of 70, all patients are symptomatic. OPMD was reported in >30 countries worldwide, with a low estimated occurrence that can be as high as 1:600 in specific communities (Blumen et al., 1997) . OPMD is caused by short expansions of a (GCG) 6 triplet repeat to (GCG) [8] [9] [10] [11] [12] [13] in the PABPN1 gene (trePABPN1), which results in the expansion of a polyalanine stretch from 10 to 12-17 alanines in the amino terminus of the protein (Brais et al., 1998) . Disease mutant (mut) trePABPN1 induces nuclear protein aggregation and forms filamentous nuclear inclusions, a pathological hallmark of OPMD (Calado et al., 2000; Thomé et al., 1997) . How the triplet-expansion mutations affect PABPN1 activity and cellular behavior is currently unknown. To study OPMD, a transgenic mouse model was developed that expresses mut trePABPN1 (A17) under the control of the muscle-specific human skeletal actin promoter (Davies et al., 2005) . trePABPN1 (A17) mice appear normal at birth but develop a progressive muscle weakness that is accompanied by the formation of trePABPN1 (A17) -containing aggregates in the nuclei of skeletal myocytes and by accelerated apoptosis (Davies and Rubinsztein, 2011; Davies et al., 2005) .
Here, using a wide-scale RNAi screen focused on human RBPs, we identified PABPN1 as a suppressor of APA. Loss of PABPN1 resulted in a global enhancement of proximal CSs usage in independent human cellular systems. In a mouse model for OPMD, as well as in human cells, the expression of a disease mut trePABPN1 (A17) also resulted in an extensive enhancement of proximal CSs. Our results elucidate a role for PABPN1 in suppressing APA sites and predict a role for unbalanced APA in OPMD.
RESULTS
An RNAi Screen Identifies PABPN1 as a Regulator of APA We designed a reporter system (named pSTAR; a plasmid system to identify APA regulators) to identify factors that regulate the usage of APA sites. We cloned downstream to the Renilla luciferase in psiCHECK2 (psiC) an $1 kb region of the 3 0 UTR of the mixed leukemia lymphoma gene (MLL), recently discovered to strongly repress luciferase expression, mainly at the level of RNA synthesis (Figures 1A; Figure S1A available online; Gomez-Benito et al., 2011) . Physical engagement of RNA polymerase (Pol) II with transcription of this MLL region results in repression and low luciferase counts. Next, we cloned the proximal alternative PAS region of Cyclin D2 (CCND2; Mayr and Bartel, 2009 ) upstream of the MLL insert and used the mutated PAS as control (pSTAR-D2
WT , pSTAR-D2 mut ; Figures 1A, S1A, and S1B). We expected that the Renilla luciferase repression by MLL-3 0 UTR in pSTAR would be weakened due to early cleavage mediated by the CCND2 PAS in pSTAR-D2
WT . Figures   1A and S1C show that the MLL-3 0 UTR repressor reduced the Renilla/Firefly (R/F) ratio by more than 10-fold by lowering the Renilla luciferase expression. As expected, the insertion of CCND2 wild-type (WT) proximal PAS significantly relieved the repression, and this relief was less effective when that PAS was mutated ( Figure 1A ). Sequence analysis of transcript ends downstream of the Renilla gene in pSTAR-D2
WT revealed the exact expected CS ( Figure S1B ). Similar effects were observed with the p27 (CDKN1B) 3 0 UTR distal PAS region (Figures 1B and S1D), albeit this PAS showed a stronger effect, which is consistent with it being the strongest functional PAS of the p27 gene ( Figures 1B and S4C ). Therefore, in both cases our pSTAR reporter system successfully monitored PAS activity.
Next, we performed an RNA interference (RNAi) library screen to identify RBP genes required for APA. We reasoned that knocking down genes involved in APA should attenuate the difference in R/F ratios measured for the WT and mutant proximal CCND2 PAS constructs. Thus, we transfected pSTAR-D2
WT and -D2 mut into U2OS cells and reverse transfected siRNA smart pools designed to target 489 RBP genes ( Figure S1E ). The R/F ratio of pSTAR-D2 WT was compared to that of -D2 mut ( Figure 1C ). Genes were ranked according to the relative difference between R/F ratios for pSTAR-D2
WT and -D2 mut (Table S1 ). The top-scoring candidate in this screen (i.e., the candidate that minimized the gap between pSTAR-D2 WT and -D2 mut ) was PABPN1 ( Figure 1C , red point). To validate this result, we tested each individual small interfering RNA (siRNA) from the PABPN1 smart pool. All four siRNAs effectively silenced PABPN1 expression and diminished the difference between pSTAR-D2 WT and -D2 mut (Figures 1E and 1D) . siRNA #1 and #2 were the most efficient ones. This effect of PABPN1 knockdown (kd) was confirmed at the mRNA level ( Figure S1F ). Detailed examination of the effect of PABPN1 kd showed that in addition to its effect on the relative pSTAR-D2-WT/mut counts, it also lowered the basal R/F ratio ( Figure 1E ).
However, the latter effect was observed also in the control pSTAR vector ( Figure 1F , upper panel), indicating it is not related to PABPN1's role in regulating the usage of the CCND2-PAS insert. Intriguingly, the attenuation of the gap between pSTAR-D2 WT and -D2 mut caused by PABPN1 kd did not result from Figure S1G ). To further ascertain PABPN1's involvement in the regulation of CCND2-PAS usage, we constructed siRNA-resistant PABPN1 expression vectors for siRNAs #1 and #2. Expression of the siRNA-resistant PABPN1 proteins restored in the presence of PABPN1 siRNAs #1 and #2 the difference in R/F ratio of WT versus mut CCND2-PAS to levels observed by WT PABPN1 overexpression ( Figure 1H ). We confirmed PABPN1 kd and reconstitution by siRNA-resistant constructs with immunoblotting ( Figure 1I ). Altogether, our results indicate that in the absence of PABPN1, early cleavage occurred efficiently in both the pSTAR-D2 WT and -D2 mut constructs, suggesting that loss of PABPN1 activated a dormant CS in the CCND2-proximal PAS region to mediate an early cleavage in the mut PAS construct.
Loss of PABPN1 Induces Global 3 0 UTR Shortening To examine the role of PABPN1 in PAS selection on a global scale, we applied a deep-sequencing-based technique adapted from Beck et al. (2010) and named 3 0 Seq ( Figure S2A ). 3 0 Seq allows precise mapping of 3 0 -end cleavage and poly(A) sites at a nucleotide resolution based on the alignment of sequenced reads that span the CS and therefore cover the beginning of the untemplated poly(A) tail ( Figures S2B and S2C ). We applied 3 0 Seq to four independent U2OS-transfected control and two PABPN1 kd samples. Analyzing the 3 0 Seq dataset, we identified 23,635 CSs, of which 58% mapped to 3 0 UTRs of 9,345 transcripts ( Figure S2D ). 2,990 (32%) transcripts contained more than one CS in their 3 0 UTR ( Figure S2E ). We benchmarked these CSs against annotated CSs recorded in the poly(A) database (Lee et al., 2007) or in Ozsolak et al. (2010) and found 11,407 (83%) of the 3 0 UTR CSs to overlap with at least one of these resources but only 2,227 (22%) of other CSs ( Figure S2F ). Therefore, in subsequent analyses, we included only CSs that mapped to 3 0 UTRs. We next searched for enriched sequence motifs in the region of ±50 nt with respect to the CSs. The most enriched signal in this region was the canonical AAUAAA PAS (corresponding to AATAAA on the DNA level). Also, all major variants of the canonical signal were highly enriched too, with AUUAAA being the second most prominent motif, appearing together with the canonical signal in $60% of the mapped CSs ( Figure S2G ). As an additional indication for the precision of the CS mapping by 3 0 Seq, the location distribution of the major PAS signals showed a sharp peak at the documented position $20 nt upstream of the CSs ( Figure S2H ) . De novo motif discovery analysis also detected enriched T/TG motifs, which, in accordance with previous reports Lutz, 2008; Nunes et al., 2010) , peaked downstream of the CSs ( Figure S2I ).
Next, we examined the effect of PABPN1 kd on PAS selection. We identified 572 transcripts that showed a significant shift in CS usage in PABPN1 kd versus control samples (p < 0.001; chi-square test; Table S2A ). In more than 90% of these transcripts, the shift in CS usage was toward the proximal PASs (p < 10
À99
; binomial tail), indicating an extensive 3 0 UTR shortening in the absence of PABPN1 (Figures 2A and 2B ). We validated by quantitative polymerase chain reaction (qPCR) and northern blot the increase in the level of the short relative to the long isoform for selected genes ( Figures 2C and S2M ). The northern blot showed for the majority of the examined genes that PABPN1 kd results in elevated (absolute) levels of the short isoform, indicating that the increase in the short/long ratio in the absence of PABPN1 was associated with enhanced cleavage at the proximal PASs ( Figure S2M , right panel). To quantify the relative usage of each PAS in a transcript, we defined the PAS usage index (PUI; Extended Experimental Procedures). Comparison of the proximal PUI distribution in PABPN1 kd versus control samples further demonstrated the significantly enhanced usage of proximal PASs in the absence of PABPN1 (Figures 2D and 2E) .
To confirm the effect of PABPN1 kd on PAS selection, we applied 3 0 Seq to a second cell line (RPE-1). Here too, PABPN1 kd resulted in a broad 3 0 UTR shortening ( Figures S2N-S2P ). Of the 357 transcripts with a significant shift in CS usage, 291 (82%) showed 3 0 UTR shortening in the PABPN1 kd samples (p = 3.97 * 10 À35 ) ( Figure S2Q ).
These results strongly suggest that PABPN1 kd causes a significant shift toward proximal PAS usage. Therefore, we sought to identify sequence features that potentially differ (B) Same experiments as in (A), but a region encompassing the p27-PAS (p27 WT and p27 mut ; Figure S1D ) was used. (C) U2OS cells were transfected with pSTAR-D2
WT and -D2 mut constructs, reverse transfected with siRNA smart pools targeting 489 RBP genes (384-well format; Figure S1E ). Standardized differences between log 2 of R/F ratios measured in the pSTAR-D2 WT and -D2 mut constructs are shown for each targeted gene. See also Figure S1 and Table S1 . between proximal and distal sites. Analyzing the set of transcripts containing exactly two 3 0 UTR CSs, we found a significantly higher prevalence of the canonical PAS, but not of its variants, in distal versus proximal sites (49% versus 27%, respectively; Table S3 ). This difference was even more pronounced in the subset of transcripts, which showed significant 3 0 UTR shortening in the PABPN1 kd samples (Table S3) , suggesting that PABPN1 kd enhances the usage of noncanonical proximal PASs.
Loss of PABPN1 Enhances mRNA Cleavage Mediated by Proximal PASs PABPN1 kd significantly increased the usage of proximal CSs relative to distal ones in hundreds of transcripts, and for several transcripts, a clear upregulation of the short form was observed by northern blots ( Figure S2M ). However, it is possible that PABPN1 kd globally destabilized transcript isoforms with longer 3 0 UTRs (e.g., due to broad activation of miRNA activity or RBPs).
To examine this possibility, we measured the stability of short and long transcript isoforms for several genes that showed a significant shift toward the proximal PAS in PABPN1 kd samples. We used 3 0 -end qRT-PCR to distinguish between the stability of isoforms with short and long 3 0 UTRs (generated by cleavage at proximal and distal CSs, respectively). To check the validity of the 3 0 -end qRT-PCR method, we first examined the relatively unstable p27 transcript. Standard qRT-PCR measurement of p27 mRNA stability showed that p27 mRNA from U2OS cells has a half-life of $2 hr ( Figure 3A) . No significant change in p27 stability was observed in PABPN1 kd cells (Figure 3A) . When the same total RNA samples were examined with 3 0 -end qRT-PCR covering the p27-PAS sequence, similar p27 stability was found, and again no significant effect of PABPN1 kd was seen ( Figure 3B , left panel). 3
0 -end qRT-PCR applied to b-actin mRNA expectedly revealed a highly stable transcript ( Figure 3B , right panel). Thus, stability estimates obtained by 3 0 -end qRT-PCR agree with those obtained with standard qRT-PCR. Moreover, PABPN1 kd did not significantly change the stability of these two single PAS-containing genes.
Next, we applied 3 0 -end qRT-PCR to compare the stability of the long and short 3 0 UTR transcript isoforms of PSMD8, SUPT6H, PDRG1, E2F1, and CCND1 that showed a strong shift toward the proximal PAS following PABPN1 kd. Regardless of the stability of the 3 0 end observed in control cells (e.g., PSMD8 is highly stable, whereas PDRG1 is relatively unstable), PABPN1 kd had no significant effect on the stability of all five transcripts ( Figures 3C, 4D, and S3A ). qRT-PCR demonstrated an efficient PABPN1 kd ( Figure 3D ). We conclude that a global destabilization of longer transcripts is not a major cause of the broad shift toward proximal PASs observed in the absence of PABPN1.
Next, we examined the transcription along MAPKAPK3, PDRG1, and E2F1, which showed significantly elevated usage of the proximal relative to the distal CS in PABPN1 kd cells. If proximal PAS usage is indeed activated, reduced levels of Pol II occupancy should be detected in the 3 0 UTR downstream of the proximal PAS following loss of PABPN1 expression. Conversely, if destabilization of the longer transcript causes the relative increase in the usage of the proximal versus the distal PAS, no change in Pol II levels along the 3 0 UTR should be observed in PABPN1 kd samples. Chromatin immunoprecipitation (ChIP) from extracts of control and PABPN1 siRNA-transfected cells showed that for these genes, but not for p27 (negative control), PABPN1 kd significantly reduced Pol II interaction with distal 3 0 UTRs relative to coding sequence (CDS) ( Figure 3E ). This indicates an early termination of Pol II transcription in the absence of PABPN1 and supports the conclusion that a reduced level of PABPN1 results in activation of proximal CSs.
PABPN1 Regulation of Proximal CSs
The extensive activation of proximal CSs in the absence of PABPN1 can result from enhanced activity of the pre-mRNA 3 0 -end processing machinery. A recent study identified >90 proteins that constitute this processing complex (Shi et al., 2009) . Global upregulation of the set of genes encoding these factors accompanies the broad 3 0 UTR shortening observed during enhanced cellular proliferation (Ji et al., 2009 and unpublished data) . To examine whether a similar induction of 3 0 -end processing genes underlies the 3 0 UTR shortening in the absence of PABPN1, we used the 3 0 Seq data to derive gene expression estimates and compared the expression of these genes between control and PABPN1 siRNA-transfected U2OS cells. However, no global change in the expression of genes involved in the 3 0 -end processing was detected in PABPN1 kd samples (Figure S3B ). This indicates that the absence of PABPN1 does not activate proximal CSs through global induction of the 3 0 -end processing machinery.
Another possible explanation for activated proximal CS usage in the absence of PABPN1 is a direct interaction of PABPN1 with proximal PAS regions, which are typically weaker than distal signals. Such binding of PABPN1 may compete with PAS recognition and/or mRNA cleavage complexes and thus can reduce cleavage efficiency at these sites. To examine this model, we (B) Five hundred and seventy-two transcripts showed a significant shift (p < 0.001; chi-square test; see Extended Experimental Procedures) in CS usage between PABPN1 kd and control samples. In 523 of these transcripts, absence of PABPN1 enhanced the usage of the proximal site relative to the distal one, resulting in overall 3 0 UTR shortening. (p value calculated using binomial tail.) (C) To confirm the results of the 3 0 Seq, the same samples as in (B) were subjected to qRT-PCR. Results were normalized to siControl #1 and shown as
Comparison between the distribution of the PUI of the proximal sites in the PABPN1 kd and control samples. The significant shift to the right demonstrates that PABPN1 kd resulted in a global increase of proximal PAS usage (p value was calculated using Wilcoxon test). The analysis included the 572 transcripts that showed significant shift in CS usage.
(E) The median of the proximal sites PUI distribution, calculated over all transcripts with more than one 3 0 UTR CS, was taken as a global measure for the usage of proximal CSs in each sample. PABPN1 kd resulted in a marked increase in this measure. See also Figure S2 and Tables S2A and S3. tested PABPN1 interaction with proximal PAS regions in vivo. We immunoprecipitated PABPN1 from U2OS cells that were subjected to 4-thiouridine and ultraviolet (UV) crosslinking treatments. Then we performed qRT-PCR with reverse oligos immediately downstream of the proximal CSs of SUPT6H, MAP-KAPK3, and hnRNPUL2 in order to distinguish unprocessed transcripts from cleaved and polyadenylated isoforms (Figure S3C) . Such primer setting is essential because PABPN1 strongly associates with poly(A) tails inside nuclei, and this binding may overshadow PABPN1 binding to regions adjacent to proximal CSs. As control for the specificity of the PABPN1 binding, we used qRT-PCR primers mapping to coding regions ( Figure S3C ). The proximal PAS regions of all three genes examined were significantly enriched for PABPN1 binding ( Figure 3F ). We then examined whether PABPN1 binds to proximal PAS regions in vitro. We synthesized the proximal hnRNPUL2 PAS including 30 nt down-and upstream and used RNA-electromobility shift assays (R-EMSA) to examine the binding of recombinant PABPN1 (rPABPN1) to this radiolabeled proximal PAS region (Kü hn et al., 2009) . We observed rPABPN1 binding that was largely dependent on the integrity of the PAS sequence, as mutating the triple A of the PAS to triple C clearly reduced rPABPN1 binding to this region ( Figure 3G ). rPABPN1 binding to the WT PAS region was efficiently competed with cold WT, but not mutated, PAS sequence ( Figure 3H ). This indicates specific binding to the PAS region. Similar results were obtained with the proximal MAPKAPK3 PAS region and increasing rPABPN1 amounts ( Figures 3I and S3D) . These results suggest a direct effect of PABPN1 on proximal PAS usage.
Next, we performed in vitro cleavage assays to test whether PABPN1 directly regulates PAS-mediated cleavage. We used in vitro synthesized RNA probes comprising the proximal PAS regions of MAPKAPK3, hnRNPUL2, and SUPT6H and the distal PAS region of MAPKAPK3. In these probes, the CS of the MAPKAPK3 distal PAS region is located $10 nt from the 3 0 end, and the CSs of MAPKAPK3, hnRNPUL2, and SUPT6H proximal PAS regions at $25-30 nt from the 3 0 end ( Figure S3E ). As controls, we used probes with mutated PAS sequence (AAA to CCC, designated WT to mut). When incubating these probes with nuclear extract of HeLa cells transfected with control siRNAs ( Figure 3J , lane C), we observed efficient and specific cleavage of the canonical distal MAPKAPK3 region but very limited cleavage of the proximal PAS regions. PABPN1 kd (#2) enhanced cleavage of all proximal probes but not of the canonical distal one. As no cleavage products of proximal or distal probes were seen when the control PAS mut probes were used, and as the lengths of the cleavage products fit the expected sizes ( Figure S3E ), we conclude that this cleavage is mediated by the 3 0 -end processing machinery and that loss of PABPN1 enhances it. Supporting this notion, adding rPABPN1 to the cleavage reaction markedly reduced PABPN1-induced cleavage efficiency ( Figure 3J , lane #2+P). PABPN1 kd was confirmed by qRT-PCR and western blotting ( Figure 3J , upper right corner). This result strongly supports a direct role for PABPN1 in suppressing PASmediated cleavage at proximal sites.
PABPN1 Contributes to Efficient 3
0 UTR-Mediated Repression Loss of PABPN1 in U2OS cells increased the usage of CCND1 proximal PAS by $2-fold ( Figures 4A-4C ). This shift was not accompanied by any stability changes of the long or the short transcript isoforms ( Figure 4D ). CCND1 is a target of the miR-17-19 cluster ( Figure 4E ), which is expressed in U2OS cells (Figure 4F) . Thus, we examined whether loss of PABPN1 attenuates CCND1 sensitivity to miR-17-19. We transfected U2OS cells with a construct containing the miR-17-19 cluster (miRVec-17-19, expressing miR-17, -18a, -20a, -19a, and -19b-1; Figure S4A) , or a control vector, and reverse transfected these cells with control and PABPN1 #1 and #2 siRNAs. Transfection of miRVec-17-19 increased miR-20a levels and suppressed CCND1 protein expression in control but not in PABPN1 siRNA-transfected cells ( Figures 4F and 4G ). To further examine the PABPN1 effect on miR-17-19-mediated repression of the CCND1 3 0 UTR, we constructed dual luciferase vectors containing either the full-length CCND1 3 0 UTR (psiC-D1-FL) or a short CCND1 3 0 UTR that terminates at the proximal CS (psiC-D1-S). The transfection of miRVec-17-19 resulted in $3.5-fold relative inhibition of the full-length CCND1 3 0 UTR compared to (C) The stability of mRNA isoforms terminated at the distal CS was measured by 3 0 -end qRT-PCR (average ± SD). In none of the cases did PABPN1 kd result in a destabilization of the longer transcript or in a stabilization of the shorter isofoms ( Figure S3A ). miRvec-Ctrl transfection ( Figure S4B , left panel). Moreover, whereas the full-length CCND1 3 0 UTR was highly repressed by miR-17-19, the short CCND1 3 0 UTR form was completely resistant ( Figure S4B, left panel) . PABPN1 kd significantly reduced miR-17-19 effect on the full-length construct (p < 0.00001; one-tailed t test; Figure 4H , left panel). To control for general effects on miRNA activity, we used p27 3 0 UTR that showed no APA in our dataset ( Figure S4C ) and contained two miR-222 target sites (le . We cotransfected the psiC-p27 3 0 UTR with miRVec-222 and observed an $2-fold relative inhibition of p27 3
0 UTR compared to miRvec-Ctrl transfection ( Figure S4B, right panel) . A construct containing mutations in the two miR-222 target sites (p27-3 0 UTR-DM) was resistant to miR-222-mediated suppression ( Figure S4B, right panel) . In contrast to CCND1, PABPN1 kd did not affect miR-222-mediated repression of p27 3 0 UTR ( Figure 4H , right panel), indicating that PABPN1 does not generally interfere with miRNA function in our system. These results provide an example for the role of PABPN1 in suppressing proximal PAS usage, thereby allowing the regulation of the target gene by its full 3 0 UTR sequence.
Extensive 3
0 UTR Shortening Caused by an OPMDAssociated PABPN1 Mutant Short triplet-repeat expansion mutations in the PABPN1 gene (trePABPN1) cause the autosomal-dominant OPMD disease. As the effect of trePABPN1 on the function of the endogenous WT PABPN1 protein is unknown, we examined whether tre-PABPN1 (A17) interacts with endogenous WT PABPN1. We mildly expressed a GFP-tagged trePABPN1 (A17) in U2OS cells and detected nuclear dots with immunostaining ( Figure 5A , marked with #). Immunohistochemistry with PABPN1 antibody revealed a colocalization of endogenous PABPN1 with GFP-tre-PABPN1 (A17) dots in transfected cells (#), whereas a rather homogenous staining in untransfected cells was seen ( Figure 5A , marked with arrows). This suggests that trePABPN1 (A17) sequesters endogenous PABPN1. If this effect is direct, one should expect binding of trePABPN1 (A17) to PABPN1. Indeed, coimmunoprecipitation reveals interaction between GFP-tre-PABPN1 (A17) and endogenous WT PABPN1 ( Figure 5B , lane 6). Next, we examined whether trePABPN1 (A17) also affects APA, as we found that loss of WT PABPN1 significantly induced the usage of proximal PASs. We transfected U2OS cells with an expression vector for trePABPN1 (A17) or a control vector and performed 3 0 Seq. trePABPN1 (A17) expression resulted in 3 0 UTR shortening: of the 134 transcripts that showed a significant shift in CS usage, 103 transcripts showed an induction of the proximal CS usage (p = 1.6 * 10 À10 ; binomial tail; Figure 5C ).
Proximal PUI analysis also demonstrated that trePABPN1 (A17) expression resulted in enhanced usage of proximal CSs ( Figures  5D and 5E ). Importantly, we observed a significant overlap between the genes that showed 3 0 UTR shortening in response to trePABPN1 (A17) overexpression and in response to endogenous PABPN1 kd (60 transcripts; p = 1.7 * 10
À7
; hypergeometric tail). These results indicate that trePABPN1 functions in a dominant-negative manner by interacting with WT PABPN1 and sequestering it to nuclear dots, and its effect on APA is similar to the effect of inhibiting WT PABPN1 by RNAi.
To study the effect of trePABPN1 function on APA in vivo, we applied 3 0 Seq to skeletal muscle tissues from an OPMD mouse model that expresses trePABPN1 (A17) (Davies et al., 2005) . This 3 0 Seq dataset included samples from OPMD mice aged 20 weeks or 12 months and their matching controls. We detected 10,849 CSs, 55% of which mapped to 3 0 UTRs. Motif analysis identified the canonical PAS as the most enriched signal in the CS regions, and its location distribution sharply peaked at the expected position $20-25 nt upstream of the mapped CSs ( Figures S6A and S6B ). In line with our findings in human cells, murine muscle tissue expressing the trePABPN1 (A17) mut showed an extensive 3 0 UTR shortening at both the age of 12 months (Figures 6A-6D ) and the age of 20 weeks ( Figures  S6C-S6E ). In the analysis of the 12-month-old mice, a total of 305 transcripts showed a significant shift in CS usage in the comparison between trePABPN1 (A17) and control muscle tissues (Table S2B) . Strikingly, 273 of them (90%, p = 3.9 * 10
À49
; binomial tail) showed elevated usage of proximal sites in the tre-PABPN1 (A17) mice ( Figure 6B ). These results detect for the first time wide-spreading abnormal APA in a model of a human genetic disorder and further strongly pinpoint PABPN1 as an important regulator of this gene regulation process.
Assuming that in many cases 3 0 UTR shortening would attenuate miRNA-mediated transcript degradation, we compared transcript expression levels between the trePABPN1 (A17) and control samples. We found that at the age of 12 months, the expression of transcripts with enhanced proximal PAS usage in trePABPN1 (A17) mice was significantly elevated in these mice compared to their expression in the WT controls ( Figure 6E) . A similar trend, but with reduced statistical significance, was observed for the 20-week-old mice ( Figure S6F ) and in U2OS cells expressing trePABPN1 (A17) ( Figure S5 ).
DISCUSSION
APA is a layer of gene regulation that to date remains largely unexplored. Yet, it is becoming evident that a large portion of human genes contain multiple CSs and PASs in their 3 0 UTRs. PABPN1 kd significantly reduced miR-17-19-mediated repression of the CCND1 full-length construct, resulting in a reduction of the relative short/long ratio of CCND1 3 0 UTR form from $3-fold to $2-fold (n = 9; mean ± SEM; one-tailed t test).
See also Figure S4 . Therefore, it is conceivable that the majority of human genes are subjected to APA regulation. The maturation of deepsequencing methods specifically designed to probe transcript 3 0 ends significantly enhances our ability to globally characterize alternative CSs and PASs and hence appreciate the full scope of APA regulation under various physiological stresses and pathological conditions. Here, we developed an RNAi screen to identify APA regulators and pinpointed PABPN1 as an important player in this process. We have adapted a deep-sequencing technique, 3
0 Seq, and applied it to obtain genome-wide views of PABPN1's role in determination of PAS usage.
PABPN1 Controls Proximal PAS Usage
Previous in vitro data indicated that PABPN1 binds to poly(A) tails and controls their extension (Kü hn et al., 2009) . It stimulates polyadenylation by the PAP enzyme but also restricts polyadenylation once the poly(A) tail reaches a certain size ($250 nt in humans). Here, we show that PABPN1 regulates APA by suppressing the usage of weak proximal PASs (Figure 7, upper and middle panel) . This suggests that PABPN1 acts prior to cleavage and polyadenylation of mRNAs to determine proper rate of proximal PAS usage.
Our in vitro and in vivo data suggest that PABPN1 directly interacts with PAS regions and by that competes with the cleavage and polyadenylation complexes on the recognition of weak proximal and noncanonical PASs. Whereas PABPN1 is likely to bind also to canonical PAS regions, the competition with polyadenylation and cleavage complexes on such regions is predicted to be much lower due to the significantly stronger recruitment of the cleavage and polyadenylation machinery to canonical PAS regions. Our in vitro cleavage assays support this notion. Canonical distal PAS regions were more active and less affected by reduced PABPN1 levels than proximal PAS regions. Nevertheless, our results cannot exclude indirect effects of PABPN1 on PAS selection, e.g., through PABPN1 association with Pol II (Bear et al., 2003) .
PABPN1 and OPMD
A GCG repeat extension in the PABPN1 gene from 6 to 8-13 triplets (trePABPN1) causes OPMD, which is characterized by progressive degeneration of particular muscles in adults (Tavanez et al., 2005) . trePABPN1 proteins induce nuclear protein aggregation and form filamentous nuclear inclusions (Calado et al., 2000; Thomé et al., 1997) . Our data support the induction of nuclear inclusion by trePABPN1 (A17) and further suggest that by binding to WT PABPN1 and sequestering it to inclusion bodies, trePABPN1 (A17) dominant negatively affects its WT protein function (Figure 7 , lower panel). Indeed, the global effect on CS selection that we elicited by ectopic expression of tre-PABPN1 (A17) resembled the effect elicited by PABPN1 kd. A transgene OPMD mouse model was developed by expressing mut trePABPN1 (A17) under the control of the muscle-specific human skeletal actin promoter (Davies et al., 2005) . In this mouse model, the expression of trePABPN1 (A17) leads to a dystrophic phenotype in the presence of two endogenous WT PABPN1 copies and mimics the progressive muscle weakness seen in OPMD patients. This observation argues as well for a toxic gain of function for trePABPN1 (A17) (Davies et al., 2005) .
We found in this mouse model a global induction of proximal PAS usage mediated by trePABPN1 (A17) . Also, it seems that aggregates of the mut protein coaggregate with WT PABPN1, which would result in depletion and reduced activity of WT PABPN1 in OPMD muscle cells. Our results imply that OPMD is associated with misregulated APA, which results in unbalanced formation of alternative mRNA 3 0 ends. They also predict that OPMD symptoms in humans may be to a certain degree a result of aberrant gene expression due to a change in 3 0 -end formation. Though our results predict a change in APA during OPMD development, it could be expected that endogenously expressed trePABPN1 in OPMD patients would present a milder APA phenotype compared to the mouse model (due to higher transgene expression) or compared to experimental conditions in which WT PABPN1 expression is dramatically reduced. To what extent trePABPN1 mutants induce aberrant APA in patient cells, and which genes and phenotypes are affected, remain to be investigated.
Possible Role of PABPN1 in Proliferation and Cancer?
Regulation of PAS usage and progressive 3 0 UTR shortening and lengthening were observed during immune cell reactivation (Sandberg et al., 2008) , cancer progression (Mayr and Bartel, 2009) , and development (Ji et al., 2009) . To date it is unknown whether PABPN1 is involved in these processes. Given that OPMD patients were so far not reported to be at higher risk of developing cancer and OPMD mouse models are not susceptible to tumor growth, it would be interesting to examine levels of PABPN1, its posttranscriptional modification status, and its function in cancer or during normal cellular differentiation.
EXPERIMENTAL PROCEDURES
Cell Culture U2OS osteosarcoma and HeLa cells and RPE-1 hTERT-immortalized retinal pigment epithelial cells were maintained in DMEM or RPMI 1640, respectively, supplemented with 10% FCS in a 5% air-humidified atmosphere at 37 C.
Transfections and Luciferase Assay
Transfection constructs were cloned as described in the Extended Experimental Procedures. Cells were transfected with psiCHECK2 constructs (Fugene6; Roche). After 72 hr, dual luciferase activity assays (Promega) were performed. Cells were transfected with PABPN1 siRNAs (final concentration: 25 nM; Dharmafect3; Dharmacon).
Coimmunoprecipitation GFP-trePABPN1 (A17) or GFP was overexpressed in U2OS cells for 2 days and immunoprecipitated with GammaBind G Sepharose beads (Ge Healthcare) using a mouse GFP antibody (Roche) or an unrelated mouse Cox-2 antibody (sc-19999, Santa Cruz Biotechnology). Cell extracts were cleared in lysis buffer (50 mM HEPES, 150 mM NaCl, 0.5% Nonidet P-40 [pH 7.5], protease inhibitor [PI; Roche]) and incubated with GFP or Cox-2 antibody overnight at 4 C. Next, the extract/antibody mix was combined with the GammaBind G Sepharose beads and incubated for 3 hr at 4 C. After washing with lysis buffer (described above), the beads were resuspended in sample buffer and subjected to immunoblotting. 0.5 mM DTT, 100 mM KCl, 2 mM MgCl 2 ) for 15 min at room temperature (RT) and was run with 2 ml loading buffer (50% glycerol, 0.1% bromophenol blue) on a native gel (6% polyacrylamide [37.5:1], 40% glycerol, and 13 TBE) for 3 hr at 220 V. The gel was exposed to a Phosphor Imaging Plate and developed on the BAS-2500 system (both Fujifilm).
R-EMSA
In Vivo Binding Assay Cells were grown overnight in medium containing 1 mM 4-thiouridine (4SU; Sigma Aldrich). Next, the cells were irradiated (365 nm UV light crosslinking; 0.15 J/cm 2 ; Stratalinker 2400) and harvested in lysis buffer (50 mM HEPES [pH 7.5], 140 mM NaCl, 1% Triton X-100, 0.1% NaDeoxycholate, PI [Roche] , RNaseOUT [Invitrogen] ). Cleared cell lysates were treated with RNA fragmentation buffer (Ambion) for 3 min at 70 C and incubated with a PABPN1
antibody (2428-1; Epitomics) or an unrelated IgG antibody (sc-2027, Santa Cruz Biotechnology) overnight at 4 C. GammaBind G Sepharose beads (GE Healthcare) were preblocked with yeast tRNA (Invitrogen) and RNase-free BSA (Ambion). Next, preblocked G Sepharose beads were combined with antibody/protein lysate mix and incubated for 4 hr at 4 C. After intensive washing, the beads were resuspended in lysis buffer (with proteinase K) and incubated for 1 hr at 50 C. RNA was extracted (Trizol; Invitrogen) and sub- jected to gene-specific cDNA synthesis and qPCR (primer: Extended Experimental Procedures).
In Vitro Cleavage Assay Assay was performed as described by Wahle and Keller (1994; Extended Experimental Procedures) . 1 3 10 7 HeLa cells were resuspended in 500 ml buffer (10 mM Tris-HCl [pH 7.8], 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, PI; Roche), homogenized (25G needle), and centrifuged at 2000 3 g for 15 min. Nuclei were resuspended in 200 ml solution (25% glycerol, 20 mM Tris-HCl [pH 7.8], 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.6 M NaCl, 0.5 mM DTT, PI; Roche). Capped (Vaccinia capping system; New England Biolabs) and 32 P-labeled RNAs were prepared with Ambion's probe construction kit and gel purified. Cleavage reactions were prepared in 12,5 ml containing 50,000 cpm of labeled RNA, 2 mM DTT, 1.5 mM MgCl 2 , 0.8 mM 3 0 dATP, 0.1 mg/ml tRNA, 3% PEG 6000, 50 mM KCl, 20 mM creatine phosphate, 40 U RNaseOUT (Invitrogen), and 12.5 ml nuclear extracts, incubated at 30 C for 2 hr, and stopped with proteinase K and SDS. RNA was extracted (Trizol; Invitrogen), precipitated, separated on a 10% acrylamide-7 M urea gel, and visualized by autoradiography.
3

-End qRT-PCR
Total RNA was extracted (RNeasy Mini kit; QIAGEN), and 3 mg was heat fragmented (fragmentation buffer; Ambion) for 5 min at 70 C. The fragmented total RNA was precipitated, the first cDNA strand synthesized (SuperScript III reverse transcriptase; P7-t25-vn oligo-dT primer; Invitrogen), and qRT-PCR performed as described above (P7-primer; gene-specific forward primers; Extended Experimental Procedures).
Animal Studies
Animal work was performed under the jurisdiction of appropriate UK Home Office Licenses.
ACCESSION NUMBERS
Raw sequence data and wig files that summarize read coverage along the chromosomes (normalized to 10 M mapped reads) are available in the Gene Expression Omnibus (GEO) database under accession number GSE27452.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six figures, and six tables and can be found with this article online at doi:10.1016/j.cell.2012.03.022.
(E) Comparison of changes in expression levels in trePABPN1 (A17) versus WT muscles samples (12-month-old mice) between two sets of transcripts: a target set containing genes that showed a significant shift toward proximal CSs in the trePABPN1 (A17) tissue and a background (BG) set containing the rest of the genes measured in our dataset (p value calculated using Wilcoxon test). See also Figures S5 and S6 and Table S2B .
